TY - JOUR
T1 - Local production of lactate, ribose phosphate, and amino acids by human triple-negative breast cancer
AU - Ghergurovich, Jonathan M.
AU - Lang, Jessica D.
AU - Levin, Maren K.
AU - Briones, Natalia
AU - Facista, Salvatore J.
AU - Mueller, Claudius
AU - Cowan, Alexis J.
AU - McBride, Matthew J.
AU - San Roman Rodriguez, Esther
AU - Killian, Aaron
AU - Dao, Tuoc
AU - Lamont, Jeffrey
AU - Barron, Alison
AU - Su, Xiaoyang
AU - Hendricks, William P.D.
AU - Espina, Virginia
AU - Von Hoff, Daniel D.
AU - O'Shaughnessy, Joyce
AU - Rabinowitz, Joshua D.
N1 - Funding Information:
We thank all of the patients who participated in this study. We also thank Ralph DeBerardinis for generously providing plasma lactate enrichment data from the studies described in Courtney et al. 47 and Shawn Davidson for the mouse circulating glucose and lactate data described in Davidson et al. 50 We thank members of the Rabinowitz laboratory for helpful comments and suggestions. The infusion scheme, red blood cell imagery, and graphical abstract were created using BioRender. The results published here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga . The clinical trial, genomic, and proteomic studies were funded by a grant from Baylor Scott & White Dallas Foundation , Dallas, Texas. Metabolite analysis was supported by NIH grants 1DP1DK113643 , P30 CA072720 (Metabolomics, Biomedical Informatics, and Biospecimen Repository Service Shared Resource, Rutgers Cancer Institute of New Jersey), and R01 CA163591 .
Funding Information:
We thank all of the patients who participated in this study. We also thank Ralph DeBerardinis for generously providing plasma lactate enrichment data from the studies described in Courtney et al.47 and Shawn Davidson for the mouse circulating glucose and lactate data described in Davidson et al.50 We thank members of the Rabinowitz laboratory for helpful comments and suggestions. The infusion scheme, red blood cell imagery, and graphical abstract were created using BioRender. The results published here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga. The clinical trial, genomic, and proteomic studies were funded by a grant from Baylor Scott & White Dallas Foundation, Dallas, Texas. Metabolite analysis was supported by NIH grants 1DP1DK113643, P30 CA072720 (Metabolomics, Biomedical Informatics, and Biospecimen Repository Service Shared Resource, Rutgers Cancer Institute of New Jersey), and R01 CA163591. J.D.R. J.O. D.D.V.H. and J.M.G. conceived the study. J.M.G. J.D.L. M.K.L. W.P.D.H. V.E. J.O. and J.D.R. designed the experiments. J.M.G. J.D.L. M.K.L. V.E. N.B. S.J.F. E.S.R.R. A.K. T.D. J.L. A.B. M.J.M. and X.S. conducted the experiments. J.M.G. J.D.L. V.E. N.B. S.J.F. C.M. X.S. A.J.C. M.J.M. J.O. and J.D.R. analyzed the data. J.M.G. and J.D.R. wrote the paper with input from the other authors. J.D.R. is a co-founder and stockholder in Toran and Serien Therapeutics and advisor and stockholder in Agios Pharmaceuticals, Kadmon Pharmaceuticals, Bantam Pharmaceuticals, Colorado Research Partners, Rafael Pharmaceuticals, Barer Institute, and L.E.A.F. Pharmaceuticals and is on the scientific advisory board for Nirogy Therapeutics. D.D.V.H. is a consultant for L.E.A.F Pharmaceuticals. V.E. is a consultant for OncBioMune d/b/a Theralink Technologies, Inc. and is listed on George-Mason-University-owned patents for laser capture microdissection and breast cancer treatment. J.D.R. and J.M.G. are listed as inventors on a Princeton University patent application concerning G6PD inhibitors.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/6/11
Y1 - 2021/6/11
N2 - Background: Upregulated glucose metabolism is a common feature of tumors. Glucose can be broken down by either glycolysis or the oxidative pentose phosphate pathway (oxPPP). The relative usage within tumors of these catabolic pathways remains unclear. Similarly, the extent to which tumors make biomass precursors from glucose, versus take them up from the circulation, is incompletely defined. Methods: We explore human triple-negative breast cancer (TNBC) metabolism by isotope tracing with [1,2-13C]glucose, a tracer that differentiates glycolytic versus oxPPP catabolism and reveals glucose-driven anabolism. Patients enrolled in clinical trial NCT03457779 and received intravenous (i.v.) infusion of [1,2-13C]glucose during core biopsy of their primary TNBC. Tumor samples were analyzed for metabolite labeling by liquid chromatography-mass spectrometry (LC-MS). Genomic and proteomic analyses were performed and related to observed metabolic fluxes. Findings: TNBC ferments glucose to lactate, with glycolysis dominant over the oxPPP. Most ribose phosphate is nevertheless produced by oxPPP. Glucose also feeds amino acid synthesis, including of serine, glycine, aspartate, glutamate, proline, and glutamine (but not asparagine). Downstream in glycolysis, tumor pyruvate and lactate labeling exceed that found in serum, indicating that lactate exchange via monocarboxylic transporters is less prevalent in human TNBC compared with most normal tissues or non-small cell lung cancer. Conclusions: Glucose directly feeds ribose phosphate, amino acid synthesis, lactate, and the tricarboxylic acid (TCA) cycle locally within human breast tumors. Funding: The clinical trial, genomics, and proteomics were funded by the Baylor Scott & White Dallas Foundation, Dallas, Texas. Metabolic analyses were supported by NIH grants 1DP1DK113643, R01CA163591, and P30CA072720.
AB - Background: Upregulated glucose metabolism is a common feature of tumors. Glucose can be broken down by either glycolysis or the oxidative pentose phosphate pathway (oxPPP). The relative usage within tumors of these catabolic pathways remains unclear. Similarly, the extent to which tumors make biomass precursors from glucose, versus take them up from the circulation, is incompletely defined. Methods: We explore human triple-negative breast cancer (TNBC) metabolism by isotope tracing with [1,2-13C]glucose, a tracer that differentiates glycolytic versus oxPPP catabolism and reveals glucose-driven anabolism. Patients enrolled in clinical trial NCT03457779 and received intravenous (i.v.) infusion of [1,2-13C]glucose during core biopsy of their primary TNBC. Tumor samples were analyzed for metabolite labeling by liquid chromatography-mass spectrometry (LC-MS). Genomic and proteomic analyses were performed and related to observed metabolic fluxes. Findings: TNBC ferments glucose to lactate, with glycolysis dominant over the oxPPP. Most ribose phosphate is nevertheless produced by oxPPP. Glucose also feeds amino acid synthesis, including of serine, glycine, aspartate, glutamate, proline, and glutamine (but not asparagine). Downstream in glycolysis, tumor pyruvate and lactate labeling exceed that found in serum, indicating that lactate exchange via monocarboxylic transporters is less prevalent in human TNBC compared with most normal tissues or non-small cell lung cancer. Conclusions: Glucose directly feeds ribose phosphate, amino acid synthesis, lactate, and the tricarboxylic acid (TCA) cycle locally within human breast tumors. Funding: The clinical trial, genomics, and proteomics were funded by the Baylor Scott & White Dallas Foundation, Dallas, Texas. Metabolic analyses were supported by NIH grants 1DP1DK113643, R01CA163591, and P30CA072720.
KW - Translation to humans
KW - Warburg
KW - [1,2-C]glucose
KW - de novo serine pathway
KW - glycolysis
KW - human tracer infusion
KW - isotope tracer
KW - lactate
KW - pentose phosphate pathway
KW - triple-negative breast cancer
KW - tumor metabolism
UR - http://www.scopus.com/inward/record.url?scp=85108731688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108731688&partnerID=8YFLogxK
U2 - 10.1016/j.medj.2021.03.009
DO - 10.1016/j.medj.2021.03.009
M3 - Article
C2 - 34223403
AN - SCOPUS:85108731688
SN - 2666-6359
VL - 2
SP - 736-754.e6
JO - Med
JF - Med
IS - 6
ER -